Glymset-M2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to reduced blood glucose levels. The combination of these two agents offers complementary mechanisms of action, providing effective glycemic regulation in patients inadequately controlled on diet and exercise alone. Glymset-M2 Tablet PR is indicated for adult patients with type 2 diabetes who require dual therapy to achieve target glycemic levels. It is essential to initiate therapy alongside lifestyle modifications including diet and physical activity. The prolonged-release formulation ensures a steady plasma concentration, potentially improving patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to any component. Glymset-M2 Tablet PR should be prescribed and used under medical supervision to optimize therapeutic outcomes and minimize adverse effects.